Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 3:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Advanced Gastric Cancer Clear all
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Gastric Adenocarcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Urothelial Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Lung Cancer AJCC v8, Unresectable Malignant Solid Neoplasm, Unresectable Melanoma
Interventions
Pembrolizumab, Sonidegib
Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced May 22, 2026, 3:48 AM EDT
Enrolling by invitation Not applicable Interventional
View directory record Official record
Conditions
Advanced Heart Failure, Advanced Non-colorectal Gastro-intestinal Cancer, Advanced Lung Cancer
Interventions
Tier - Palliative Care
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced May 22, 2026, 3:48 AM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
AMG 355, Pembrolizumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
6
States / cities
Duarte, California • Merriam, Kansas • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced May 22, 2026, 3:48 AM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Cancer
Interventions
CPI-613
Drug
Lead sponsor
Cornerstone Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced May 22, 2026, 3:48 AM EDT
Recruiting Phase 2Phase 3 Interventional
View directory record Official record
Conditions
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma
Interventions
PF-08634404, Chemotherapy, Nivolumab
Biological · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
56
States / cities
Aurora, Colorado • Boulder, Colorado • Centennial, Colorado + 47 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced May 22, 2026, 3:48 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors, Microsatellite Instability Low, Microsatellite Instability High, Microsatellite Stable, Ovarian Cancer, Gastric Cancer, Colo-rectal Cancer, Esophageal Cancer, Endometrial Cancer, Head Neck Cancer, Cervical Cancer, Lung Cancer
Interventions
NC410, pembrolizumab
Drug
Lead sponsor
NextCure, Inc.
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
17
States / cities
Tucson, Arizona • Aurora, Colorado • Edgewood, Kentucky + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2024 · Synced May 22, 2026, 3:48 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Cancers With HER2 Expression
Interventions
BAY2701439
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
4
States / cities
Baltimore, Maryland • St Louis, Missouri • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced May 22, 2026, 3:48 AM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Advanced Solid Tumors, Gastric Cancer, Gastroesophageal Junction Cancer, Urothelial Cancer, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinomas
Interventions
PF-07265028, Sasanlimab
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
6
States / cities
Scottsdale, Arizona • Iowa City, Iowa • Grand Rapids, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced May 22, 2026, 3:48 AM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Advanced Solid Tumors, MSI-H or dMMR Advanced Solid Tumors, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Colorectal Cancer, MSI-H/dMMR Gastroesophageal-junction Cancer, Endometrial Cancer, Mismatch Repair Deficient or MSI-High Solid Tumors
Interventions
EIK1005, pembrolizumab (KEYTRUDA® )
Drug
Lead sponsor
Eikon Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Morristown, New Jersey • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced May 22, 2026, 3:48 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Gastric Cancer
Interventions
Bemarituzumab, Placebo, Modified FOLFOX6
Biological · Drug
Lead sponsor
Five Prime Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
29
States / cities
Tucson, Arizona • Greenbrae, California • Sacramento, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2024 · Synced May 22, 2026, 3:48 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Advanced Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, Pancreatic Cancer
Interventions
TST001, Nivolumab Injection [Opdivo], mFOLFOX6, Gemcitabine, Albumin-Bound Paclitaxel
Drug
Lead sponsor
Suzhou Transcenta Therapeutics Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
18
States / cities
Gilbert, Arizona • Tucson, Arizona • New Haven, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced May 22, 2026, 3:48 AM EDT
Terminated No phase listed Observational
View directory record Official record
Conditions
Neoplasms, Lung Neoplasms, Colon Neoplasms, Breast Neoplasms, Pancreatic Neoplasms, Prostate Neoplasms, Kidney Neoplasms, Liver Neoplasms, Rectal Neoplasms, Hematologic Neoplasms, Multiple Myeloma, Myelodysplastic Syndromes, Ovarian Neoplasms, Bladder Neoplasms, Testicular Neoplasms, Endometrial Neoplasms, Brain Neoplasms, Biliary Tract Neoplasms, Head and Neck Neoplasms, Uterine Cervical Neoplasms, Skin Neoplasms, Melanoma, Gastric Neoplasms, Anal Neoplasms, Sarcoma
Interventions
Provider determined
Other
Lead sponsor
CureOne
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Idaho Falls, Idaho
Source: ClinicalTrials.gov public record
Updated Apr 1, 2019 · Synced May 22, 2026, 3:48 AM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Interventions
Bemarituzumab, Nivolumab, Chemotherapy, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
37
States / cities
Phoenix, Arizona • Cerritos, California • Downey, California + 31 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced May 22, 2026, 3:48 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Bladder Cancer, HER2-positive Solid Tumor
Interventions
PRS-343 in Combination with Atezolizumab
Drug
Lead sponsor
Pieris Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
8
States / cities
Los Angeles, California • Newport Beach, California • Santa Monica, California + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2024 · Synced May 22, 2026, 3:48 AM EDT
Not listed No phase listed Observational
View directory record Official record
Conditions
Therapeutic Endoscopic Ultrasound, Advanced Endoscopy, Therapeutic Endoscopy, Interventional Endoscopy, Interventional Endoscopic Ultrasound, Gastro-Intestinal Disorder, Gastrointestinal Disease, Gastrointestinal Cancer, Gastrointestinal Dysfunction, Gastrointestinal Fistula, Gastrointestinal Infection, Gastrointestinal Injury, Pancreatic Disease, Bile Duct Diseases
Interventions
Therapeutic Endoscopic Ultrasound
Procedure
Lead sponsor
Advanced Endoscopy Research, Robert Wood Johnson Medical School Rutgers University
Other
Eligibility
Not listed
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced May 22, 2026, 3:48 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Adenocarcinoma of the Gastroesophageal Junction, Gastric Adenocarcinoma, Gastric Cancer
Interventions
FDG-PET, surgery, 5-FU, capecitabine, docetaxel, Irinotecan, 3D-CRT, IMRT
Procedure · Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
71
States / cities
Los Angeles, California • St. Helena, California • Newark, Delaware + 47 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2025 · Synced May 22, 2026, 3:48 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Gastric Cancer, Gastric Adenocarcinoma, Esophageal Cancer
Interventions
Irinotecan, Cisplatin, Surgery, Floxuridine, Capecitabine
Drug · Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
3
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 7, 2018 · Synced May 22, 2026, 3:48 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
Oxaliplatin, Leucovorin, Fluorouracil, Ziv-aflibercept
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 9, 2020 · Synced May 22, 2026, 3:48 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Cancer
Interventions
isolated perfusion, melphalan
Drug
Lead sponsor
Delcath Systems Inc.
Industry
Eligibility
16 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 22, 2013 · Synced May 22, 2026, 3:48 AM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Interventions
[177Lu]Lu-DOTA-TATE, Octreotide LAR
Radiation · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 100 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
19
States / cities
Scottsdale, Arizona • Fayetteville, Arkansas • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced May 22, 2026, 3:48 AM EDT
Completed Not applicable Interventional Results available
View directory record Official record
Conditions
Cancer
Interventions
management of therapy complications, massage therapy, pain therapy, psychosocial assessment and care, quality-of-life assessment
Procedure
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 6, 2017 · Synced May 22, 2026, 3:48 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Neoplasms
Interventions
BAY1143572
Drug
Lead sponsor
Bayer
Industry
Eligibility
21 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
6
States / cities
Fayetteville, Arkansas • Boston, Massachusetts • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2017 · Synced May 22, 2026, 3:48 AM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, NSCLC, HNSCC, Head and Neck Squamous Cell Carcinoma, Esophageal Cancer
Interventions
MCLA-158, MCLA-158 + Pembrolizumab, MCLA-158 + FOLFIRI, MCLA-158 + FOLFOX
Drug · Combination Product
Lead sponsor
Merus B.V.
Industry
Eligibility
18 Years and older
Enrollment
523 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
23
States / cities
La Jolla, California • Los Angeles, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced May 22, 2026, 3:48 AM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor
Interventions
RMC-6291
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
15
States / cities
Springdale, Arkansas • Orange, California • Sacramento, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced May 22, 2026, 3:48 AM EDT